HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Decline in rates of seropositivity for measles, mumps, and rubella antibodies among previously immunized children treated for acute leukemia.

Abstract
We prospectively determined the measles-mumps-rubella (MMR) antibody status of 39 previously vaccinated children before and after administering protocol-directed chemotherapy for acute leukemia. At diagnosis the seropositivity rates for measles and mumps-specific immunoglobulin G were > or = 90%, while the seropositivity rate for rubella was 85%. After treatment, rates of seropositivity for measles antibody declined by 13% (90% of patients to 77%; P = .13); for mumps antibody, by 18% (97%-79%; P = .02); and for rubella antibody, by 21% (85%-64%; P = .03). These findings suggest that some survivors of acute leukemia during childhood have an increased susceptibility to MMR viruses and would benefit from posttreatment evaluation of their immune statuses and from possible revaccination.
AuthorsS Feldman, M Andrew, M Norris, B McIntyre, R Iyer
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 27 Issue 2 Pg. 388-90 (Aug 1998) ISSN: 1058-4838 [Print] United States
PMID9709893 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Antibodies, Viral
  • Immunoglobulin G
  • Measles Vaccine
  • Measles-Mumps-Rubella Vaccine
  • Mumps Vaccine
  • Rubella Vaccine
  • Vaccines, Combined
Topics
  • Acute Disease
  • Adolescent
  • Analysis of Variance
  • Antibodies, Viral (blood)
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Immunoglobulin G (blood)
  • Infant
  • Leukemia (drug therapy, immunology, virology)
  • Male
  • Measles Vaccine (immunology)
  • Measles virus (immunology)
  • Measles-Mumps-Rubella Vaccine
  • Mumps Vaccine (immunology)
  • Mumps virus (immunology)
  • Prospective Studies
  • Rubella Vaccine (immunology)
  • Rubella virus (immunology)
  • Vaccination
  • Vaccines, Combined (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: